anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Because of the potential for infusion reactions, patients should receive antihistamines with or without antipyretics prior to infusion. Despite routine pretreatment with antihistamines, infusion reactions, some severe, occurred in 33 of 59 (56%) patients treated with NAGLAZYME. Serious adverse reactions during infusion included laryngeal edema, apnea, pyrexia, urticaria, respiratory distress, angioedema, and anaphylactoid reaction. Severe adverse reactions included urticaria, chest pain, rash, dyspnea, apnea, laryngeal edema, and conjunctivitis [see Adverse Reactions (6.1, 6.2)]. 

The most common symptoms of drug-related infusion reactions were pyrexia, chills, rash, urticaria, dyspnea, nausea, vomiting, pruritis, erythema, abdominal pain, hypertension, and headache. Respiratory distress, chest pain, hypotension, angioedema, conjunctivitis, tremor, and cough were also reported. Infusion reactions began as early as Week 1 and as late as Week 146 of NAGLAZYME treatment. Twenty-three of 33 patients (70%) experienced recurrent infusion reactions during multiple infusions though not always in consecutive weeks.

Symptoms typically abated with slowing or temporary interruption of the infusion and administration of additional antihistamines, antipyretics, and occasionally corticosteroids. Most patients were able to complete their infusions. Subsequent infusions were managed with a slower rate of NAGLAZYME administration, treatment with additional prophylactic antihistamines, and, in the event of a more severe reaction, treatment with prophylactic corticosteroids.

If severe infusion reactions occur, immediately discontinue the infusion of NAGLAZYME and initiate appropriate treatment. The risks and benefits of re-administering NAGLAZYME following a severe reaction should be considered.

No factors were identified that predisposed patients to infusion reactions. There was no association between severity of infusion reactions and titer of anti-galsulfase antibodies.
PROBLEM TO BE SOLVED: To obtain an antiviral and an antimicrobial agents, containing a furanonaphthoquinone derivative and having excellent activity and little side effect. SOLUTION: The agents contain a compound of the formula [R is R', OR', etc., (R' is H, an alkyl, a hydroxyalkyl or an alkoxyalkyl) or adjacent R groups may form a heterocarbon ring via an oxygen atom] as an active component. As an example of a compound of the formula, 2-methylnaphtho[2,3-b]furan-4,9- dione is cited. A compound of the formula can be obtained by a known chemical synthetic method, or by the extraction, etc., of a naphthoquinone from bark, etc., as a natural product. The agent is effective on an RNA viral disease such as Japanese encephalitis, dengue, rubeola, mumps, rubella, influenza, viral hepatitis A, viral hepatitis C, chronic rheumatoid arthritis or systemic lupus erythematosus. Further, the agent exhibits excellent antimicrobial activity on Eumycetes, Gram negative bacteria, etc.
Metabolic dysfunction-associated steatotic liver disease affects 1 in 4 people in the United States and western Europe, with an important proportion developing metabolic dysfunction-associated steatohepatitis (MASH), the progressive subtype of metabolic dysfunction-associated steatotic liver disease. Cirrhosis caused by MASH is a leading indication for liver transplantation and the most common cause of hepatocellular carcinoma. Hitherto, there have been no specific pharmacotherapies for MASH. The recent conditional approval by the Food and Drug Administration of resmetirom for the treatment of moderate or advanced MASH presents a much-anticipated therapeutic option for patients with noncirrhotic advanced MASH. Specifically, the intended population for resmetirom are patients with MASH and fibrosis stages 2 or 3. The approval of resmetirom also presents important challenges, including how to noninvasively identify patients with fibrosis stages 2-3, and how to exclude patients with more advanced disease who should not be treated until further data emerge on the use of resmetirom in this population. Herein we consider the available literature with regard to identifying the intended population for treatment with resmetirom and in proposing criteria for stopping treatment.
Bust d'Odor Deodorant is a clear liquid roll-on deodorant for men and women with lemon juice and botanical extracts (honeysuckle and orange lemongrass). It is designed to remove strong underarm odor that may last up to 48 hours. There are no antiperspirants, which is the whole objective of this invention. It does not prevent sweating as do antiperspirants, because sweating is good for the human body. To prevent underarm sweat is to keep toxins or waste products in the body; and adding the chemicals in antiperspirants on top of this makes it very dangerous and unhealthy for the human body. This is a breakthrough invention for mankind, health-wise. It has no side effects except for minor itch caused by cuts from shaving. It leaves no residue or gummy, sticky feeling under armpit, and does not stain or discolor clothing.
Consult with a Certified Poison Control Center (1-800-222-1222) for up-to-date guidance and advice for treatment of overdosage. Individual patient response to amphetamines varies widely. Toxic symptoms may occur idiosyncratically at low doses.

Manifestations of amphetamine overdose include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Serotonin syndrome has been reported with amphetamine use, including lisdexamfetamine dimesylate capsules. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.

Lisdexamfetamine and d-amphetamine are not dialyzable.
Heparin is a heterogenous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans having anticoagulant properties. Although others may be present, the main sugars occurring in heparin are: (1) α-L-iduronic acid 2-sulfate, (2) 2-deoxy-2-sulfamino-α-D-glucose 6-sulfate, (3) β-D-glucuronic acid, (4) 2-acetamido-2-deoxy-α-D- glucose, and (5) α-L-iduronic acid. These sugars are present in decreasing amounts, usually in the order (2) > (1) > (4) > (3) > (5), and are joined by glycosidic linkages, forming polymers of varying sizes. Heparin is strongly acidic because of its content of covalently linked sulfate and carboxylic acid groups. In heparin sodium, the acidic protons of the sulfate units are partially replaced by sodium ions.

Heparin Sodium in Sodium Chloride Injection is a buffered, sterile, nonpyrogenic solution of Heparin Sodium, USP derived from porcine intestinal mucosa, standardized for anticoagulant activity supplied in single dose containers for vascular administration. It contains no antimicrobial agents. The potency is determined by a biological assay using a USP reference standard based on units of heparin activity per milligram. Composition, osmolarity, pH and ionic concentration are shown in Table 1.

This VIAFLEX PLUS plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). VIAFLEX PLUS on the container indicates the presence of a drug additive in a drug vehicle. The VIAFLEX PLUS plastic container system utilizes the same container as the VIAFLEX plastic container system. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
Ribavirin is known to accumulate in intracellular components from where it is cleared very slowly. It is not known whether ribavirin contained in sperm will exert a potential teratogenic effect upon fertilization of the ova. In a study in rats, it was concluded that dominant lethality was not induced by ribavirin at doses up to 200 mg/kg for 5 days (estimated human equivalent doses of 7.14 to 28.6 mg/kg, based on body surface area adjustment for a 60 kg adult; up to 1.7 times the maximum recommended human dose of ribavirin). However, because of the potential human teratogenic effects of ribavirin, male patients should be advised to take every precaution to avoid risk of pregnancy for their female partners.

Females of childbearing potential should not receive combination ribavirin capsules/INTRON A therapy unless they are using effective contraception (two reliable forms) during the therapy period. In addition, effective contraception should be utilized for 6 months posttherapy based on a multiple dose half-life (t1/2) of ribavirin of 12 days.

Male patients and their female partners must practice effective contraception (two reliable forms) during treatment with combination ribavirin capsules/INTRON A therapy and for the 6-month posttherapy period (e.g., 15 half-lives for ribavirin clearance from the body).

If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment cessation, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at (800) 593-2214.
Diabetic foot is one of the major complications observed in patients with diabetes. Diabetic foot can lead to non-traumatic lower-limb amputation (LLA), and is confirmed to be associated with cognitive decline and worsening quality of life. Previous studies indicated that diabetics had a 25% lifetime risk of developing diabetic foot, and 14% to 24% of those require amputation. In patients with poor results of conservative treatment, amputation is the main terminal treatment option to avoid the spread of infection.

Amputation in diabetic foot patients may linked to different causes, including inflammatory, infectious and malignant conditions. A retrospective cohort based on Shandong Provincial Qianfoshan Hospital Healthcare Big Data Platform is conducted to evaluate the progression and prognosis of diabetic foot patients. A prediction model will be developed to identify high-risk diabetic foot patients of amputation and provide a scientific basis for personalized clinical care.
Patients with chronic heart failure on treatment with bisoprolol and/or ramipril will be included. Study will consist of two study visits: baseline visit (V1) and visit which will be performed at least 6 months after baseline (V2). At both visits same procedures will be performed. On the day of the visit, patients will be asked to take their morning dose of bisoprolol and/or ramipril after the withdrawal of the first morning plasma sample. Additional 3 to 5 plasma samples will be taken within 5 hours post bisoprolol and/or ramipril dose in order to determine pharmacokinetic profile of both drugs. Body composition will be measured by bioimpedance and dual-energy X-ray absorptiometry. Renal function will be measured by clearance of intravenously administered iohexol. Biochemical parameters, muscle strength, fatigue and anorexia will be assessed in order to determine presence of cachexia.

Changes in body composition will be correlated with changes in pharmacokinetic parameters of bisoprolol and ramipril. Pharmacokinetic parameters in cachectic patients will be compared to pharmacokinetic parameters in non-cachectic patients. Parameters of body composition will be correlated with the difference between measured and estimated renal function.
PURPOSE:To obtain a new compound useful for multiple drug resistant cancer treatment, having conquering action on anticancer drug resistance of cancer cell having acquired anticancer drug resistance. CONSTITUTION:A polyene compound shown by the formula. Properties: molecular weight: 492. Solubility: soluble in methanol, carbon tetrachloride and chloroform and slightly soluble in water. Shape: yellow oily substance at normal temperature. The compound is obtained by culturing a fungus (e.g. Muxococcus steibitus AJ12, 587) belonging to the genus Muxococcus a common culture method, isolating and purifying.
OBJECTIVES: To differentiate invasive lepidic predominant adenocarcinoma (iLPA) from adenocarcinoma in situ (AIS)/minimally invasive adenocarcinoma (MIA) of lung utilizing visual semantic and computer-aided detection (CAD)-based texture features on subjects initially diagnosed as AIS or MIA with CT-guided biopsy.
MATERIALS AND METHODS: From 2011 to 2017, all patients with CT-guided biopsy results of AIS or MIA who subsequently underwent resection were identified. CT scan before the biopsy was used to assess visual semantic and CAD texture features, totaling 23 semantic and 95 CAD-based quantitative texture variables. The least absolute shrinkage and selection operator (LASSO) method or forward selection was used to select the most predictive feature and combination of semantic and texture features for detection of invasive lung adenocarcinoma.
RESULTS: Among the 33 core needle-biopsied patients with AIS/MIA pathology, 24 (72.7%) had invasive LPA and 9 (27.3%) had AIS/MIA on resection. On CT, visual semantic features included 21 (63.6%) part-solid, 5 (15.2%) pure ground glass, and 7 (21.2%) solid nodules. LASSO selected seven variables for the model, but all were not statistically significant. "Volume" was found to be statistically significant when assessing the correlation between independent variables using the backward selection technique. The LASSO selected "tumor_Perc95", "nodule surround", "small cyst-like spaces", and "volume" when assessing the correlation between independent variables.
CONCLUSIONS: Lung biopsy results showing noninvasive LPA underestimate invasiveness. Although statistically non-significant, some semantic features showed potential for predicting invasiveness, with septal stretching absent in all noninvasive cases, and solid consistency present in a significant portion of invasive cases.
PURPOSE: A composition containing tea extract and lactic acid bacteria is provided to suppress cancer cell proliferation and to prevent or treat intestinal diseases. CONSTITUTION: A composition for preventing or treating intestinal diseases contains 0.0001-90 wt% of tea extract and 0.1-20 wt% of lactic acid bacteria. The tea extract contains catechin including epigallocatechin gallate, epigallocatechin, epicatechin gallate, or epicatechin. The lactic acid bacteria include Lactobacillus plantarum or Lactobacillus paracasei. A method for preparing the composition comprises a step of extracting tea which is fermented with the lactic acid bacteria. [Reference numerals] (AA) Negative control group; (BB) Catechin; (CC,FF) Lactobacillus paracasei; (DD,GG) Lactobacillus rhamnosus; (EE,HH) Lactobacillus acidophilus
ERCP is the best option to remove bile duct stones. It can be done by either endoscopic sphincterotomy (EST) or endoscopic papillary balloon dilation (EPBD). Large bile duct stones appear to be more difficult to remove with conventional methods, such as EST and EPBD. Therefore, extraction of large bile duct stones may require mechanical lithotripsy (ML) as an adjunctive procedure. The primary complication of ML is basket and stone impaction, which can lead to complications such as pancreatitis and cholangitis. Some recent studies have reported the efficacy of endoscopic papillary large balloon dilation (EPLBD) alone or combined with limited EST, establishing it as a safe treatment for the removal of large bile duct stones. The investigators conducted the present study to compare the therapeutic outcome and complications between EPLBD alone and limited EST plus EPLBD for the treatment of large bile duct stones.
A method of preparing sunscreens in which a dispersion of zinc oxide particles in an oil is formed by milling in the presence of a particulate grinding medium and mixed with cosmetically acceptable materials is claimed. The particles of zinc oxide have an average size of from 0.005 to 0.15 micron and the dispersion is substantially transparent to visible light but with an extinction coefficient at 308 nm (E(308)) and at 360 nm (E(360)) of at least 9 liters per gram per centimeter. The ratio E(360):E(308) is in the range 0.75:1 to 1.5:1. In a preferred method a mixed dispersion containing titanium dioxide and zinc oxide, having E(308) at least 15 liters per gram per centimeter, E(360) at least 10 liters per gram per centimeter and the ratio E(360):E(308) in the range 0.3:1 to 1.5:1 is used. The mixed dispersion is also claimed. The sunscreens prepared have a good balance of absorption for UVA and UVB radiation and better SPF values than those prepared from titanium dioxide and/or zinc oxide powders.
Viscose yarn has incorporated therein at least 15 per cent by weight of an X-ray detectable material such as barium sulphate. The yarn may also contain a coloured pigment, for identification purposes.  One or more of the yarns may be woven into surgical dressings.  The barium sulphate, or the like, is added to the spinning solution as a dry powder having a particle size of less than 4 microns after the main filtration but before the solution is filtered in the spinning machine, the spinning machine filter being wadding weighing 300 gms./square metre.  The solution is spun from a spinneret having holes of at least 100 microns, preferably 120 microns, to a final yarn denier of at least 3000. In an example, viscose containing 8 per cent cellulose and 6.5 per cent alkali was filtered twice through wadding and to the filtrate was added 8 per cent by weight of dry barium sulphate of particle size 1 micron.  The mixture was agitated for 30 mins. with a high-speed stirrer and then de-aerated by standing for 6 hrs. under a reduced pressure of 2 lb. per sq. in. absolute.  The viscose was passed through cotton wadding weighing 300 gms. per sq. metre and spun form a spinneret having 720 holes of 120 micron diameter into a bath containing 9 per cent sulphuric acid, 4 per cent magnesium sulphate, 1 per cent zinc sulphate and 18 per cent sodium sulphate.  The spinning speed was 65 metres/minute and the stretch 30 per cent.  After bleaching, dyeing and conditioning the final denier was 10,000 and the barium sulphate content 48 per cent. In a second example, 10 per cent of the filtered viscose solution was mixed with 42 per cent by weight of the dry barium sulphate by means of a paddle and circulation through a pipe containing a reed vibrating at supersonic frequency.  The solution was then centrifuged, added to the remaining 90 per cent of the filtered viscose solution together with 0.01 per cent of the total weight of iso-octyl alcohol to prevent formation of stable froth, the whole mixed and de-aerated under reduced pressure.  The mixture was spun through a spinneret having 480 holes of 120 micron diameter to give a thread of 7000 denier containing 28 per cent of barium sulphate, two of these threads after desulphurizing and drying being twisted together to form the final detector thread.  In a third example, 0.1 per cent of a 20 per cent aqueous suspension of a blue insoluble pigment of 1 micron particle size was added to the viscose for identification purposes.
The invention discloses a novel antibiotic for treating drug-resistant gram-positive bacteria and tuberculosis. The structural formula of the novel antibiotic is shown as formula I, wherein in the formula I, a group R 1 Hydrogen, alkyl with 1-15 carbon atoms, alkenyl with 2-15 carbon atoms, alkynyl with 2-15 carbon atoms, aryl or acyl; radical R 2 Hydrogen, halogen, alkyl with 1-15 carbon atoms, alkenyl with 2-15 carbon atoms, alkynyl with 2-15 carbon atoms, aryl or acyl; radical R 3 Is an alkyl group having 1 to 15 carbon atoms. The compound shown in the formula I provided by the invention can be used for inhibiting the growth and/or reproduction of gram-positive bacteria. Based on the fact that the existing gram-positive bacteria have serious drug resistance, the invention provides a novel antibacterial compound. The invention synthesizes a series of teixobactin analogues by a solid-phase and liquid-phase combination method for the first time, and a convergent synthesis strategy is adopted to be beneficial to synthesizing a plurality of compounds. The compound with the activity equivalent to that of teixobactin is prepared by the invention.
Compositions and methods are provided for cell growth on an oriented collagen film. The cells may be grown in vitro, e.g. the culture of cells, including regenerative cells such as stem cells, lineage committed progenitors, etc. Cells may also be grown in vivo, e.g. where an oriented collagen thin film provides a substrate for cell growth, e.g. as a wound covering or artificial skin construct.
Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects).
All participants received a placebo at first vaccination (Month 0). Participants \<12 years received hepatitis A at second (Month 6) and third (Month 12) vaccinations. Participants \>= 12 years received influenza vaccine of Northern and Southern hemisphere formulations at second (Month 6) and third (Month 12) vaccinations.
An aerosol preparation assembly includes an entrainment chamber defining an entrainment volume. The entrainment chamber includes a gas inlet port, an aerosol inlet port and an outlet port. The entrainment chamber is configured such that a velocity of a flow of a gas within the entrainment volume is less than a velocity of the flow of the gas within the gas inlet port. The entrainment chamber is configured such that at least a portion of inlet aerosol is entrained into the flow of the gas within the entrainment volume to produce an entrained aerosol flow at the outlet port. The particle selection chamber is configured to receive the entrained aerosol flow and produce an outlet aerosol flow. The particle selection chamber and nozzle are collectively configured such that a volumetric median diameter of the outlet aerosol flow is less than a volumetric median diameter of the inlet aerosol.
In order to determine the sample size, power analysis was performed using the G\*Power Version 3.1.9.2 program. Effect size of 1.26 was set up for the VAS pain score changes between groups as per the previous study. For power calculations, a confidence level (α) of 0.05 and a power level of 0.95 was assumed. Fifteen patients per group in each center was required. 15 patients were randomized to two groups in each center by numbered envelopes method. The group 1 and group 2 notes were put into to the closed envelopes separately, and each patient randomly chose an envelope and gave it to a physician who was not the researcher. One researcher evaluated the patient and then collected the data, and the second researcher who was certified as KT practitioner applied the KT. Both patients and the researcher who recorded the data were blinded to treatment allocation.